Literature DB >> 30348711

Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer.

Tetsuo Saito1, Ryo Toya2, Naoya Yoshida3, Takashi Shono4, Tomohiko Matsuyama2, Satoshi Ninomura2, Takahiro Watakabe2, Yutaka Sasaki4, Hideo Baba3, Natsuo Oya2.   

Abstract

AIM: Our study sought to identify dosimetric predictors of treatment-related lymphopenia during chemoradiotherapy for esophageal cancer.
MATERIALS AND METHODS: Patients with esophageal cancer who had received definitive chemoradiotherapy at our Institution were retrospectively assessed. The absolute volume of the spleen, body, and bone marrow that had received 5, 10, 20, and 30 Gy and the mean splenic dose were recorded.
RESULTS: Multivariate linear regression analysis revealed that docetaxel use and spleen dose-volume parameters (V5, V10, V20, V30, and mean splenic dose) were significant independent factors negatively influencing the absolute lymphocyte count at nadir. An increase of 1 Gy in mean splenic dose predicted a 2.9% decrease in nadir absolute lymphocyte count. Univariable logistic regression analysis showed that the mean splenic dose was a significant predictor of grade 4 lymphopenia. None of the body or bone marrow dose-volume parameters significantly predicted lymphopenia.
CONCLUSION: Higher spleen dose-volume parameters were associated with severe lymphopenia during chemoradiotherapy. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Treatment-related lymphopenia; bone marrow; chemoradiotherapy; dose–volume parameters; spleen

Mesh:

Year:  2018        PMID: 30348711      PMCID: PMC6365734          DOI: 10.21873/invivo.11409

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  23 in total

1.  The sensitivity of lymphocytes to ionising radiation.

Authors:  O A TROWELL
Journal:  J Pathol Bacteriol       Date:  1952-10

2.  Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay.

Authors:  N Nakamura; Y Kusunoki; M Akiyama
Journal:  Radiat Res       Date:  1990-08       Impact factor: 2.841

3.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

4.  Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.

Authors:  A Kotsakis; E Sarra; M Peraki; M Koukourakis; S Apostolaki; J Souglakos; E Mavromanomakis; J Vlachonikolis; V Georgoulias
Journal:  Cancer       Date:  2000-09-15       Impact factor: 6.860

Review 5.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.

Authors:  Haruo Ohtani
Journal:  Cancer Immun       Date:  2007-02-21

Review 6.  The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.

Authors:  Sandra Demaria; Karsten A Pilones; Claire Vanpouille-Box; Encouse B Golden; Silvia C Formenti
Journal:  Radiat Res       Date:  2014-06-17       Impact factor: 2.841

7.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.

Authors:  Chunyan Gu-Trantien; Sherene Loi; Soizic Garaud; Carole Equeter; Myriam Libin; Alexandre de Wind; Marie Ravoet; Hélène Le Buanec; Catherine Sibille; Germain Manfouo-Foutsop; Isabelle Veys; Benjamin Haibe-Kains; Sandeep K Singhal; Stefan Michiels; Françoise Rothé; Roberto Salgado; Hugues Duvillier; Michail Ignatiadis; Christine Desmedt; Dominique Bron; Denis Larsimont; Martine Piccart; Christos Sotiriou; Karen Willard-Gallo
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

8.  The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells.

Authors:  Susannah Yovino; Lawrence Kleinberg; Stuart A Grossman; Manisha Narayanan; Eric Ford
Journal:  Cancer Invest       Date:  2013-02       Impact factor: 2.176

9.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.

Authors:  K Hiraoka; M Miyamoto; Y Cho; M Suzuoki; T Oshikiri; Y Nakakubo; T Itoh; T Ohbuchi; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Aaron T Wild; Xiaobu Ye; Susannah G Ellsworth; Jessica A Smith; Amol K Narang; Tanu Garg; Jian Campian; Daniel A Laheru; Lei Zheng; Christopher L Wolfgang; Phuoc T Tran; Stuart A Grossman; Joseph M Herman
Journal:  Am J Clin Oncol       Date:  2015-06       Impact factor: 2.339

View more
  14 in total

Review 1.  Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Dongjun Dai; Qiaoying Tian; Genhua Yu; Yongjie Shui; Hao Jiang; Qichun Wei
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma.

Authors:  Tsz Him So; Sik Kwan Chan; Wing Lok Chan; Horace Choi; Chi Leung Chiang; Victor Lee; Tai Chung Lam; Ian Wong; Simon Law; Dora Kwong; Feng Ming Spring Kong; Jian Yue Jin; Ka On Lam
Journal:  Adv Radiat Oncol       Date:  2020-04-19

3.  Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study.

Authors:  Wang Jing; Yufei Liu; Hui Zhu; James Welsh; Saumil Gandhi; Melenda Jeter; Quynh Nguyen; Aileen B Chen; Michael O'Reilly; Zhongxing Liao; Joe Y Chang; Percy Lee; Steven H Lin
Journal:  Clin Transl Radiat Oncol       Date:  2021-03-12

Review 4.  Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

Authors:  Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

5.  Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer.

Authors:  Daniel W Kim; Grace Lee; Hwan Lee; Jack M Qian; Nina N Sanford; Miranda B Lam; Naeem Tahir; Harvey J Mamon
Journal:  Adv Radiat Oncol       Date:  2019-12-31

6.  Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies.

Authors:  Anirudh Yalamanchali; Hong Zhang; Ke Colin Huang; Radhe Mohan; Steven H Lin; Cong Zhu; Stuart A Grossman; Jian-Yue Jin; Susannah G Ellsworth
Journal:  Adv Radiat Oncol       Date:  2020-08-10

Review 7.  Lymphopenia in Esophageal Cancer: What Have We Learned?

Authors:  Jia-Lin Wang; Rong Ma; Wei Kong; Ren Zhao; Yan-Yang Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

8.  Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients.

Authors:  Xin Wang; Zongxing Zhao; Peiliang Wang; Xiaotao Geng; Liqiong Zhu; Minghuan Li
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

9.  Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome.

Authors:  Bhanu Prasad Venkatesulu; Amrish Sharma; Julianne M Pollard-Larkin; Ramaswamy Sadagopan; Jessica Symons; Shinya Neri; Pankaj K Singh; Ramesh Tailor; Steven H Lin; Sunil Krishnan
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.996

10.  Excessive splenic volume is an unfavorable prognostic factor in patients with non-small cell lung cancer treated with chemoradiotherapy.

Authors:  Jianping Guo; Lei Wang; Xiaoyan Wang; Luo Li; Yajuan Lü; Congcong Wang; Chong Hao; Jiandong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.